Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 12/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25046782 | 1.00 | CA2 (0.45) | CA2METTL3ADKPRMT5MTOR | |
| SCHEMBL30941639 | 0.88 | MTOR (0.53) | CA2METTL3ADKPRMT5MTOR | |
| SCHEMBL30940751 | 0.88 | METTL3 (0.54) | CA2METTL3ADKPRMT5 | |
| SCHEMBL25047864 | 0.88 | MTOR (0.53) | CA2METTL3ADKPRMT5MTOR | |
| SCHEMBL25048821 | 0.88 | METTL3 (0.56) | CA2METTL3PRMT5 | |
| SCHEMBL30941053 | 0.88 | METTL3 (0.56) | CA2METTL3PRMT5 | |
| SCHEMBL25046806 | 0.88 | METTL3 (0.54) | CA2METTL3ADKPRMT5 | |
| SCHEMBL30941348 | 0.87 | CA2 (0.52) | CA2METTL3ADK | |
| SCHEMBL25048825 | 0.87 | CA2 (0.52) | CA2METTL3ADK | |
| SCHEMBL25046807 | 0.86 | METTL3 (0.52) | CA2METTL3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | CA2 3376/4885METTL3 166/4885ADK 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.